4 Relapsing MS Treatments Added to UK Health Service After Cuts to Prices Agreed

4 Relapsing MS Treatments Added to UK Health Service After Cuts to Prices Agreed

After an agreement to lower their prices, four treatments for relapsing multiple sclerosis — Biogen’s Avonex and Merck KGaA‘s Rebif (both interferon beta-1a), NovartisExtavia (interferon beta 1b), and Teva’s Copaxone (glatiramer acetate) — were recommended as cost-effective and long-term therapy options within the National Health Service covering England and Wales.

The guidance decision was issued by the National Institute for Health and Care Excellence, known as NICE, and marked a change from its December finding recommending only Extavia. The discounts in prices agreed to by the manufacturers were not disclosed.

Guidance by NICE decides which treatments are funded by the National Health Service in the U.K. and made available to patients. By law, the NHS is obliged to fund medicines recommended by advisory bodies like NICE.

“This is good news for people with relapsing-remitting multiple sclerosis. We are grateful that the companies have been able to agree reductions to the NHS prices of these drugs so they can be made routinely available and ensure that people continue to benefit from a choice of treatment,” Meindert Boysen, director of the center for health technology evaluation at NICE, said in a press release.

“Multiple sclerosis is lifelong condition that can have a negative impact on people’s ability to work, and to engage in social and family life. Having treatments that can delay the progression of the disease is important to help patients get back to their normal lives,” Boysen added.

The draft guidance did not cover Bayer’s Betaferon, an interferon beta-1b, as a treatment option because it was considered not cost effective. Plegridy (peginterferon beta 1a), another Biogen therapy, will be evaluated separately.

Before publication of this NICE recommendation, Avonex, Extavia and Copaxone were available on the NHS through the Department of Health’s Risk Sharing Scheme (RSS) and commissioned by the NHS in England according to specific criteria, outlined here.

MS associations in the U.K. welcome the NICE decision, detailed here.

“People with MS told us what restricted drug options would mean for them and we’re delighted NICE has listened. This decision means people can continue to access a wide range of MS treatments. It’s vital that individuals have that choice, so they can find what best suits their needs and lifestyles. This is a great outcome and we’ll keep working to make sure everyone with MS can get the right treatment at the right time,” said Phillip Anderson, head of policy for the MS Society.

About 85 percent of MS patients are first diagnosed with relapsing MS, marked by relapses or exacerbations followed by periods of partial or complete recovery (remissions). Unlike progressive types of MS, relapses represent new inflammatory attacks on the central nervous system.

Avonex, Extavia and Copaxone are disease-modifying treatments designed to reduce disease activity and progression.



  1. Senator says:

    What about people with PPMS, when there is only one drug to combat it, Ocrevus, are you still just looking at cost ? That is something to consider when no other option is available. I was surprised when Ocrevus was fast tracked by FDA, then approved so quickly. It then was approved quickly by Medicare so I was able to get it. Ocrevus replaced Solumedrol as it performed the functions of alleviating pain and gave strength in legs. Not sure the cost of Solumedrol, but I guess Ocrevus cost is lowered in changing drug for drug.

  2. Kim says:

    I had to fight like crazy to stay on the brand name Copaxone. After horrible reactions to the generic version of copaxone my insurance company allowed me to go back to the brand name but of course they increased my copay. It’s amazing that insurance companies are allowed to take away options for patients.

    • Gail says:

      What kind of “horrible reactions” did you have to the generic Copaxone Kim? My insurance cut off my Copaxone and is making me switch. It I am very hesitant as the generic was only tested two years on mice!t

  3. LAURIE says:

    I’ve taken all the DMTs and I am worse off for it. None of it worked for me. In hindsight, I wish I had never taken any of these drugs. I was left scarred, mutilated, and no better off. The benefits went to the drug companies and to doctor kickbacks. Everyone should refuse these drugs and stop the money train. I wonder what they’d do then.

Leave a Comment

Your email address will not be published. Required fields are marked *

Pin It on Pinterest

Share This